Bionomics To Host Corporate Update And Discuss End-Of-Phase 2 Meeting Outcomes On The Development Of BNC210 In PTSD On July 31, 2024 At 8:00 am ET
Author: Benzinga Newsdesk | July 29, 2024 04:52pm
Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3 on Wednesday, July 31 at 8:00 am ET.
Posted In: BNOX